Thermo Fisher Scientific Inc. (NYSE:TMO) announced a quarterly dividend on Friday, November 8th, RTT News reports. Shareholders of record on Tuesday, December 17th will be given a dividend of 0.19 per share by the medical research company on Wednesday, January 15th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.24%. The ex-dividend date of this dividend is Monday, December 16th.
NYSE TMO opened at $320.50 on Friday. The business’s 50-day moving average price is $306.43 and its two-hundred day moving average price is $290.55. Thermo Fisher Scientific has a 12 month low of $208.34 and a 12 month high of $322.17. The firm has a market capitalization of $127.55 billion, a PE ratio of 28.82, a price-to-earnings-growth ratio of 2.06 and a beta of 1.12. The company has a current ratio of 1.80, a quick ratio of 1.23 and a debt-to-equity ratio of 0.56.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 EPS for the quarter, beating analysts’ consensus estimates of $2.88 by $0.06. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. The firm had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.19 billion. During the same quarter in the previous year, the company posted $2.62 EPS. The business’s revenue was up 5.9% on a year-over-year basis. As a group, analysts forecast that Thermo Fisher Scientific will post 12.33 earnings per share for the current fiscal year.
A number of research firms have commented on TMO. Robert W. Baird upped their price target on Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Stifel Nicolaus began coverage on Thermo Fisher Scientific in a research report on Thursday, November 14th. They issued a “buy” rating and a $345.00 price target on the stock. ValuEngine lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Evercore ISI upgraded Thermo Fisher Scientific to an “outperform” rating in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $317.00.
In related news, CEO Marc N. Casper sold 47,729 shares of the company’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the sale, the chief executive officer now owns 328,960 shares in the company, valued at approximately $97,332,684.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.45% of the stock is owned by corporate insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: What is Blockchain?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.